REAUTHORIZATIONS.

SEC. 507. REAUTHORIZATIONS. (a) Pediatric Advisory Committee.—Section 14(d) of the Best Pharmaceuticals for Children Act (42 U.S.C. 284m note) is amended by striking “during the five-year period beginning on the date of the enactment of the Best Pharmaceuticals for Children Act of 2007” and inserting “to carry out the advisory committee’s responsibilities under sections 505A, 505B, and 520(m) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a, 355c, and 360j(m))”. (b) Pediatric Subcommittee of the Oncologic Drugs Advisory Committee.—Section 15(a)(3) of the Best Pharmaceuticals for Children Act (Public Law 107-109), as amended by section 502(e) of the Food and Drug Administration Amendments Act of 2007 (Public Law 110-85), is amended by striking “during the five-year period beginning on the date of the enactment of the Best Pharmaceuticals for Children Act of 2007” and inserting “for the duration of the operation of the Oncologic Drugs Advisory Committee”. (c) Humanitarian Device Exemption Extension.—Section 520(m)(6)(A)(iv) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360j(m)(6)(A)(iv)) is amended by striking “2012” and inserting “2017”. (d) Program for Pediatric Study of Drugs in PHSA.—Section 409I(e)(1) of the Public Health Service Act (42 U.S.C. 284m(e)(1)) is amended by striking “to carry out this section” and all that follows through the end of paragraph (1) and inserting “to carry out this section, $25,000,000 for each of fiscal years 2013 through 2017.”.